SCHEMBL25375893

SCHEMBL25375893

CC[C@H](C)CNCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PDE2A O00408 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TRPV3 Q8NET8 6/20 0.38
CNR1 P21554 2/20 0.37
CNR2 P34972 1/20 0.37
POLB P06746 2/20 0.37
MBOAT4 Q96T53 1/20 0.36
DAO P14920 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
GLS O94925 1/20 0.35
HPGD P15428 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25374923 1.00 KDM1A (0.42) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL25374926 1.00 KDM1A (0.42) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL23757911 0.87 KDM1A (0.45) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL29685743 0.87 KDM1A (0.45) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL23774971 0.84 KDM1A (0.43) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL30471983 0.82 KDM1A (0.48) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL10288360 0.82 KDM1A (0.48) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL25377333 0.80 KDM1A (0.45) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL24258303 0.79 KDM1A (0.46) KDM1AMAOAMAOBPDE2ANPC1
SCHEMBL30481847 0.79 KDM1A (0.46) KDM1AMAOAMAOBPDE2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 KDM1A 650/4885MAOA 495/4885MAOB 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.